Ganglioside antigen of DU-PAN-2 in a human pancreatic cancer  by Hamanaka, Yuichiro et al.
FEBS Letters 353 (1994) 48-52 
FEBS 14617 
Ganglioside antigen of DU-PAN-2 in a human pancreatic cancer 
Yuichiro Hamanakaa’*, Sumiko Hamanakab, Yuji Shinagawa”, Takashi Suzuki”, 
Fuyuhiko Inagaki”, Minoru Suzukid, Akemi Suzukid 
“Second Department of Surgery of Yamaguchi University School of Medicine, 1144 Kogushi, Ube, Yamaguchi 755, Japan 
bDepartment of Dermatology, Yamaguchi Rosai Hospital, Onoda. Yamaguchi 756, Japan 
Departments of “Molecular Physiology and ‘Membrane Biochemistry, Tokyo Metropolitan Institute of Medical Science, Bunkyo-ku, Tokyo 113, Japan 
Received 27 July 1994; revised version received 30 August 1994 
Abstract DU-PAN-2 reactive gangliosides were isolated from the tumor of a patient with pancreatic ancer (duct cell carcinoma, moderately 
differentiated adenocarcinoma), having a negative Lewis blood phenotype, and were analyzed by means of TLC-immunostaining, enzyme-linked 
immunosorbent assay (ELISA), permethylation study, ‘H NMR spectroscopy and fast atom bombardment mass spectrometry. The structures of 
the gangliosides were found to be NeuAccc2-3Gal#0-3GlcNA~l-3Ga~l-4Gly3l-l’Cer, containing normal and hydroxy fatty acids. By TLC- 
immunostaining and ELISA with chemically synthesized gangliosides, DU-PAN-2 was demonstrated to react strongly with IV3aNeuAc-Lc&er, 
weakly with IV’aNeuAc-nLc&er, and moderately with IV6ccNeuAc-Lc,Cer and IV6aNeuAc-nLc&er. Thus it was concluded that the DU-PAN-2 
reactive ganglioside in the tumor is IV3cxNeuAc-Lc,Cer and that DU-PAN-2 has a rather broad specificity. 
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1. Introduction 
DU-PAN-2 monoclonal antibody (mAb) is a prerequisite for 
the diagnosis of pancreatic cancer in patients with Lewis-nega- 
tive phenotypes [3-51. Since the establishment of the mAb in 
1982 [6], efforts to determine its epitope have been focused on 
the glycoprotein in the serum and ascites in pancreatic cancer 
patients [7,8] or in the cultured cell lines of pancreatic cancer 
[9]. However, a detailed antigen structure has not, to date, been 
published. Here we report that gangliosides recognized by DU- 
PAN-2 in the tumor of a pancreatic cancer patient with Lewis- 
negative phenotype are IV3aNeuAc-Lc&er containing normal 
and hydroxy fatty acids. In addition, ELISA and TLC-im- 
munostaining with commercially available gangliosides howed 
that DU-PAN-2 recognizes the IV3aNeuAc-Lc,Cer structure 
as the most compatible epitope but also shows considerable 
reactivity with IV6aNeuAc-LcJer and IV6aNeuAc-nLc,Cer. 
2. Materials and methods 
2.1. Materials 
A tumor specimen was obtained during a laparotomy from a 61-year- 
old female with pancreatic body cancer. Results of laboratory blood 
examination were: Lewis blood group, Le(a-,b-); CA19-9, 22 U/ml 
(normal < 37 U/ml): DU-PAN-2. 27.000 U/ml (normal < 150 U/ml): 
and sialyl-LeX-i 55’U/ml (normal ~38 U/ml). The histopathological 
diagnosis of the tumor was duct cell carcinoma nd moderately differ- 
entiated adenocarcinoma. A ganglioside mixture (GM3, GM1 GDla 
and GDlb) used as a reference was purchased from Matreya Inc. (PA, 
USA); chemically synthesized IV’czNeuAc-Lc&er, IV’txNeuAc: 
nLc,Cer. IV6aNeuAc-LcCer and IV?xNeuAc-nLc,Cer were from 
Wake Pure Chemical Industries (Tokyo); DU-PAN-2 (mouse mono- 
clonal antibody, IgM) was from Kyowa Medix (Tokyo); and biotinyl- 
ated anti-mouse IgM @chain specific, goat); Vectastain ABC kit and 
*Corresponding author. Fax: (81) (836) 35-3331. 
Abbreviations: The nomenclature used for gangliosides is baaed on the 
system of Svennerholm [1] and follows recent recommendations [2]. 
FAB, fast atom bombardment; ELISA, enzyme-linked immunosorbent 
assay; mAb, monoclonal antibody. 
DAB substrate kit for peroxidase were from Vector Laboratories Inc. 
(Burlingame, CA). Microtiter immunoassay plates (Immuron 1; flat 
bottom) were purchased from Dynatech Laboratories Inc. (Virginia). 
2.2. Extraction and isolation of gangliosides from the tumor 
Tumor tissue (18.8 g wet weight) from the patient with pancreatic 
cancer was homogenized in 60 ml of distilled water with a Warring 
blender and then extracted with 400 ml of chloroform/methanol (2 : 1, 
by vol.), and 200 ml each of chloroform/methanol (1: 1, by vol.) and 
(1: 2, by vol.). The combined lipid extract was evaporated to dryness. 
The lipids were suspended in distilled water, dialyzed against distilled 
water and dried. Crude lipids were dissolved in chloroform/methanol/ 
water (30 : 60 : 8, by vol.) and subjected to DEAE-Toyopearl(25 ml bed 
volume, acetate form). After neutral ipids had been washed with 300 
ml of chloroform/methanol/water (30: 60: 8, by vol.), the monosia- 
loganglioside fraction was eluted with 150 ml of chloroform/methanol/ 
0.02 M sodium acetate in water (30:60:8, by vol.), the disialogangli- 
oside fraction with 150 ml of chloroform/methanol/O. 1 M sodium ace- 
tate in water (30 : 60 : 8, by vol.), and the polysialoganglioside fraction 
with chloroform/methanol/l M sodium acetate in water (30:60: 8. bv 
vol.). The three ganglioside fractions were dialyzed against distilled 
water and lyophilized. 
The monosialoganglioside fraction, which contained DU-PAN-2- 
positive gangliosides, was subjected to alkaline treatment with 0.1 N 
KOH in methanol for 2 hat 37“C. After neutralization with acetic acid, 
the fraction was desalted by Sephadex LH20 column chromatography, 
as described by Nakamura et al. [lo]. Then, monosialogangliosides 
were separated by HPLC (Waters 6OOE, Millipore Corp., Milford) on 
a silica gel column (Develosil GPG-OlO-70H, 4.6 mm i.d. x 250 mm, 
Nomura Chemical Ltd., Aichi) with programmed gradient elution with 
isopropanol/n-hexane/3 N ammonium hydroxide/water, from 10% of 
170:5:15:30(byvo1.)in165:120:15:0(byvo1.)to70%,in15min[11]. 
The flow rate was 1 ml per min and oven temperature was kept at 40’ C. 
The eluate was monitored via UV absorption at 210 nm by a W 
detector with a flow cell. This HPLC gave 9 fractions. Aliquots of the 
fractions were monitored by means of TLC and TLC-immunostaining 
with DU-PAN-2 mAb. 
2.3. Permethylation study and fatty acid analysis of isolated 
gangliosides 
The isolated gangliosides were methylated with powdered sodium 
hydroxide and methyl iodide in dry dimethyl sulfoxide [12,13]. The 
permethylated gangliosides were purified by Latrobeads column chrom- 
atography [13], then hydrolyzed, reduced and acetylated [14]. The par- 
tially methylated alditol acetates were analyzed by GLC on a capillary 
column of cross-linked 5% phenylmethylsilicone, the temperature being 
programmed to rise from 170 to 24O’C at 2’C/min [15]. 
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Fatty acid methyl esters recovered with n-hexane after methanolysis 
[16] were analyzed by GLC on a capillary column at 25O”C, as previ- 
ously described [lo]. 
2.4. Mass spectrometry and ‘H NMR spectroscopy of isolated 
gangliosides 
Negative-ion fast atom bombardment (FAB) mass spectrometry of 
gangliosides was performed with a JEOL JMS-HXllO mass spec- 
trometer equipped with a JMA-DA5000 computer system, with trietha- 
nolamine as a matrix. The accelerating voltage was 8.0 kV and primary 
beam for bombardment was 6.0 kV Xe’. 
‘H NMR analysis of the isolated gangliosides was performed in 0.4 
ml of dimethyl sulfoxide-d, containing 2% D,O with a JEOL JNM 
GX-400, 4OOMHz ‘H NMR spectrometer at 60°C. Tetramethylsilane 
was used as an internal standard of chemical shifts. 
2.5. TLC-immunostaining 
The immunostaining was carried out according to the method of 
Hansson et al. [17] modified to use an avidin-biotin system. The condi- 
tions used were DU-PAN-2 mAb (1: 100 dilution) and 2 h incubation 
at room temperature, and biotinylated goat anti-mouse IgM (1:200 
dilution) and 1 h incubation at room temperature. Finally bands were 
detected with Vectastain ABC and diaminobenzidine. Washing after 
each step was performed with phosphate-buffered saline (PBS). 
As an antigen-dilution experiment, the isolated gangliosides and 
reference gangliosides (IV”czNeuAc-Lc&er, IV3aNeuAc-nL.c&er, 
IV6aNeuAc-Lc&er and IV?xNeuAc-nLc,Cer) from 0.013 to 0.5 pg, 
were developed on a silica gel plate (HPTLC; Merck) with a solvent 
system of chloroform/methanol/0.2% aqueous CaCl, (55 : 45 : 8, by 
vol.). Relative intensities of bands detected on the TLC plates were 
calculated by densitometric scanning (CS-9000, Shimadzu, Kyoto). 
2.6. Enzyme-linked immunosorbent assay (ELISA) 
Wells of microtiter plates were each coated with 100 ng of the gangli- 
osides. The wells were incubated with DU-PAN-2 solution (1: 12.5 to 
1:25600) for 2 h at room temperature, then with biotinylated anti- 
mouse IgM (1: 200 dilution) for 1 h, and then Vectastain ABC solution 
for 1 h. After each step, the solutions were washed three times with PBS. 
Peroxidase activity in each well was detected with 50~1 each of 1.27 mM 
H202 and 2.5 mM 4aminoantipyrine in 0.17 M phenol, The absorbance 
of the developed color was measured at 490 nm after incubation at 37’C 
for 30 min. 
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3. Results 
3.1. D U-PAN-2 reactive gangliosides of pancreatic cancer 
The pancreatic tumor contained GM3 as the major gangli- 
oside and several gangliosides migrating slower than GM3 (Fig. 
1A). Of these gangliosides, two bands migrating slower than 
GM3 and faster than GMl, reacted with DU-PAN-2 mAb 
(Fig. 1B). The two bands, named gangliosides X and Y, were 
separated by ion-exchange column chromatography and 
HPLC. The yields of gangliosides X and Y were approximately 
37 ,ug and 32 pg from 18.8 g wet tissue, respectively. Gangli- 
osides X and Y co-migrated with IV3aNeuAc-Lc,Cer and 
IV3aNeuAc-nLc&er, respectively, but not with IV?zNeuAc- 
Lc&er and WaNeuAc-nI&er. 
3.2. Structural characterization of DU-PAN-2 reactive 
gangliosides 
In a permethylation study by GLC, both gangliosides were 
demonstmted to contain 2,3,btri-0-methyl-1,4,5-tri-&cetylglu- 
citol; 2,4,6-&i-@methyl-l ,3,5-tri-O-acetylgalactitoh 4&h-O-meth- 
yl-1,3,5-tri-O-acetyl-2-deoxy-2-N-methylacetamidoglucitoh and 
3,bdi-O-methyl-l,4,5-tri-O-acetyl-2deoxy-2-N-methylacetamido- 
glucitol in a molar ratio of 1.00:2.13:0.89:0.18 for ganglioside 
X and 1 .OO : 2.15 : 0.89 : 0.05 for ganglioside Y. No other alditol 
acetates could be observed by GLC. These results indicate that 
ganglioside X is IV3aNeuAc-LcJer and contains about 18% 
of ganglioside containing 4-substituted GlcNAc, and gangli- 
oside Y is IV3aNeuAc-Lc,C!er and contains about 5% of gangli- 
oside containing 4-substituted GlcNAc, both of these contami- 
nated gangliosides being possibly IV3aNeuAc-nLc,Cer. 
GLC analysis of fatty acids demonstrated that ganglioside X 
contained C16:O and C24: 1, and ganglioside Y, Cl6 : 0 and 
C24h: 1, as the major fatty acids. 
As shown in Fig. 2, in the negative-ion FAB mass spectra of 
gangliosides X and Y, two major pseudo-molecular ions 
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Fig. 1. TLC and TLC-immunostaining of isolated gangliosides from pancreatic ancer. The gangliosides were developed with a solvent system of 
chloroform/methanol/O.296 aqueous CaCl, (55:45:8, by vol.). They were detected with resorcinol-HCl reagent (A) and immunostaining with 
DU-PAN-2 mAb (B). Lanes: st, reference gangliosides, a, GM3; b, GMl; c, GDla; and d, GDlb; M, monosialogangliosides from pancreatic ancer; 
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1680 
M/Z 
NeuAcet2-3Gal l31-3GIcNAclM-3Gal l31-4GIcl31-1'Cer 






E4 5.0 4.6 4.2 (~)  
Fig. 3. 'H NMR spectra of gangliosides X (A) and Y (B). 
([M-H]-) were detected at mlz 1516 and 1626 (Fig. 2A) and 1516 
and 1642 (Fig. 2B), which are consistent with the values calcu- 
lated for the proposed structures with C16:0- and C24:1-C18 
sphingenine (Fig. 2A) and C16:0- and C24h: 1-C18 sphingen- 
ine (Fig. 2B), respectively. In these mass spectra, the ions re- 
sponsible for the successive limination of sugar moieties were 
detected at mlz 1225 and 1335 (Fig. 2A) and 1225 and 1351 (Fig. 
2B) for ([M-H-NeuAc]-); at mlz 1063 and 1173 (Fig. 2A) and 
1063 and 1189 (Fig. 2B) for ([M-H-NeuAc-Gal]-); at m/z 860 
and 970 (Fig. 2A) and 860 and 986 (Fig. 2B) for ([M-H-NeuAc- 
GaI-GlcNAc]-); at mlz 698 and 808 (Fig. 2A) and 698 and 824 
(Fig. 2B) for ([M-H-NeuAc-Gal-GlcNAc-Gal]-); and at 536 
and 646 (Fig. 2A) and 536 and 662 (Fig. 2B) for ([M-H-NeuAc- 
GaI-GlcNAc-GaI-Glc]-). 
The identification was further supported by the results of IH 
NMR spectroscopy, asshown in Fig. 3. In the anomeric proton 
region of ganglioside X (Fig. 3A), four signals can be seen at 
4.18 (J = 8.0 Hz), 4.24 (7.4 Hz), 4.28 (6.7 Hz) and 4.79 (8.0 Hz) 
ppm, which were identified as anomeric protons of fl-glucose 
(I), fl-galactose (II), fl-galactose (IV) and fl-N-acetylglucosa- 
mine (III), respectively. In the anomeric proton region of gan- 
glioside Y (Fig. 3B), four of the five anomeric signals which can 
be seen at the same chemical shift as those of gangiioside X, 
were identified as fl-glucose (I), fl-galactose (II), fl-galactose 
(IV) and fl-N-acetylglucosamine (III) at 4.18 (J = 7.9 Hz), 4.24 
(8.0 Hz), 4.28 (6.7 Hz) and 4.79 (8.6 Hz) ppm, respectively. An 
additional signal observed at 4.21 ppm (8.0 Hz) was identified 
as fl-glucose (I') of the molecule containing r~-hydroxy fatty 
acids (Sako et al. reported that the ct-hydroxy group oftbe fatty 
Y: Hamanaka et al. IFEBS Letters 353 (1994) 48-52 51 
acid moiety affects the chemical shift of the anomeric proton 
ofg-glucose [18,19]). 
3.3. Reactivity of gangliosides X and X and sialyllacto- and 
neolacto-tetraosylceramides to DU-PAN-2 
On TLC-immunostaining with antigen dilutions, as shown in 
Fig. 4, ganglioside X and Y and IV3aNeuAc-Lc,Cer exhibit 
similar binding activity, confirming that the structures of gan- 
gliosides X and Y are IV%xNeuAc-Lc&er from immunological 
reactivity. In addition, DU-PAN-2 reacts moderately with 
IV6aNeuAc-Lc,Cer and IV6aNeuAc-nLc,$er and signiticantly 
less so with IV3aNeuAc-nLc,Cer. In ELISA with antibody 
dilutions (Fig. 5) gangliosides X and Y exhibit similar binding 
activities to IV3aNeuAc-Lc,Cer. It was found that IV6aNeuAc- 
Lc,,C!er and IV6aNeuAc-nLc,Cer exhibited moderate reactivity 
while IV3aNeuAc-nLc,Cer showed little reactivity. On the basis 
of these results obtained through TLC-immunostaining and 
ELISA, it is concluded that DU-PAN-2 has a rather broad 
specificity, reacting with NeuAca2-6 derivatives as well as 
IV3aNeuAc-LqCer. 
Considering all results, we conclude that the structures of the 
gangliosides which reacted with DU-PAN-2 in the cancer tissue 
are IV3aNeuAc-Lc&!er containing normal and hydroxy fatty 
acids, and that DU-PAN-2 has a rather broad specificity. 
4. Discussion 
For one decade, studies into the DU-PAN-2 epitope have 
been performed using mu&-like molecules from the serum and 
ascites of patients with pancreatic cancer, or cultured cancer 
cell lines [8,9,17]. However, the epitope structure has not been 
elucidated. To date, summarized information is as follows: the 
epitope (i) is on a mucin-like substance or glycoprotein, (ii) is 
sensitive to neuramidase and alkaline reduction, (iii) is stable 
on heating for more than 15 min, (iv) does not react with more 























Fig. 4. TLC-immunostaining with antigen dilutions. Various amounts 
of the gangliosides (2-3Lc,, IV’aNeuAc-LcJer; 2-3nLc,, IV3ccNeuAc- 
nI_c&er; 2-6Lc.,, IV?cNeuAc-LcJZer; 2-6nLc,, IV’kcNeuAc-nLc&er; 
X, gangliosides X; and Y, ganglioside Y) were applied on a HPTLC 
plate and developed with a solvent system of chloroform/methanol/ 
0.2% aqueous CaC& (55 : 45 : 8, by vol.). The bands were detected with 
DU-PAN-2 mAb (1: 200 dilution) and ABC amplification. The intensi- 
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Fig. 5. ELISA with DU-PAN-2 mAb dilution. The gangliosides (2- 
3Lc,, IV3aNeuAc-Lc&er; 2-3&c.,, IV’aNeuAc-nLc,Cer; 2-6Lc,, 
~6aNeWk-Lc@x; 2-6nLc,, IV6aNeuAc-nLc.,Cer2-6; X, ganglioside 
X; and Y, ganglioside Y), at 0.1 &well, were incubated with a serial 
dilution of DU-PAN-2 mAb. 
galactose, GlcNAc, GalNAc and sialic acid. On the other hand, 
the fact that the sera of Lewis-negative patients with pancreatic 
cancer seldom react with CA19-9 mAb but often with DU- 
PAN-5 allows us to assume that the precursor (defucosyl sialyl 
Lea) of sialyl Le” may be the epitope of DU-PAN-2. In fact, 
Magnani, in a preliminary report stated that the epitope re- 
cognized by DU-PAN-2 antibody was NeuAca23Gal/?l- 
3GlcNA@1-3Gah?1-4Glc [20]. 
We obtained pancreatic cancer tissues from a Le(a-,b-) 
patient exhibiting a high value in the DU-PAN-2 clinical test 
and were able to confirm that the gangliosides detected with 
DU-PAN-2 mAb in the cancer are IV3aNeuAc-Lc.&er con- 
taining normal and hydroxy fatty acids. Ganglioside fractions 
other than the monosialoganglioside fraction did not exhibit 
any bands detected by DU-PAN-2, confirming the antigen in 
the cancer tissue to be IV3aNeuAc-Lc$er. On TLC im- 
munostaining of ganglioside fractions obtained from the sera 
of patients exhibiting high values of DU-PAN-2, no bands were 
detected, indicating that DU-PAN-2 antigen in sera would be 
carbohydrate chains of glycoproteins but not of gangliosides. 
Gangliosides contain single carbohydrate chains while 
glycoproteins have heterogeneous and multiple carbohydrate 
chains on one molecule, and therefore, in the determination of 
epitope structure, gangliosides have the advantage. 
In our immunological studies, DU-PAN-2 reacted strongly 
with IV3aNeuAc-Lc,Cer, and moderately with IV6a euAc- 
LcJJer and IV6aNeuAc-nLc&er. IV3aNeuAc-nLc,Cer showed 
little reactivity to the antibody. At present, it is difficult to 
explain how DU-PAN-2 can react with NeuAca2-6 derivatives 
but interesting to note that it does so, especially at high concen- 
trations of antigen. It might be possible that, if we can produce 
a mAb which reacts with IV3aNeuAc-Lc,Cer in a more specific 
manner, we can reduce the number of false-positive cases. 
Our results for the gangliosides of the pancreatic cancer 
tissue confirmed that the gangliosides recognized by DU-PAN- 
2 are IV’aNeuAc-Lc&er but not IV3aNeuAc-nLc,Cer, 
IV6aNeuAc-Lc,Cer or IV6aNeuAc-nLc&er. 
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